Table 1.

Contents of the “breast cancer” MLPA kit P078-B1 (MRC Holland)

Gene	Chrom	Gain (%)	Amp (%)	Loss (%)	Function and clinical relevance
ESR1	06q25.1	6	0	3	Transcription factor; under debate [40–42]
EGFR	07p11.2	22	1	0	Signal transduction; poor survival [4]
FGFR1	08p11.23	29	13	0	Signal transduction; poor survival, tamoxifen resistance [5]
ADAM9	08p11.23	39	11	1	Protein metabolism; promotes invasion [38]
IKBKB	08p11.21	32	6	0	Signal transduction [43]
PRDM14	08q13.3	32	9	0	Transcription regulatory protein; chemoresistance [44]
MTDH	08q22.1	49	12	0	Signal transduction; promoting metastases, chemoresistance, poor survival [36]
MYC	08q24.21	36	10	0	Transcription factor; poor survival [3]
CCND1	11q13.2	46	18	1	Signal transduction; ER positivity, poor survival [35]
EMSY	11q13.5	10	2	3	Transcription regulatory protein; poor survival [45]
CDH1	16q22.1	6	0	9	Cell adhesion [46]
TRAF4	17q11.2	41	4	0	Signal transduction [47]
CPD	17q11.2	9	0	0	Protein metabolism [48]
MED1	17q21.2	23	4	0	Transcriptional coactivator; ER positivity [49]
HER2	17q12	17	4	0	Signal transduction; bad survival; trastuzumab response [2]
CDC6	17q21.2	41	4	0	Signal transduction [50]
TOP2A	17q21.2	26	2	0	Regulation of the topological status of DNA; poor survival, susceptible for certain chemotherapy [6]
MAPT	17q21.31	16	0	0	Microtubule stabilization; chemoresistance (taxanes) [51]
BIRC5	17q25.3	27	2	0	Signal transduction; predict distant recurrence [52]
CCNE1	19q12	2	0	1	Signal transduction; poor survival [53]
AURKA	20q13.31	10	4	12	Signal transduction [54]

For each gene, chromosome location (Chrom), gene copy number gain (Gain; >1.3), amplification (Amp; >2.0), gene loss (Loss; <0.7), function and clinical relevance (in female breast cancer) are shown